Literature DB >> 1637658

Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents.

A Gescher.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1637658      PMCID： PMC1977896          DOI： 10.1038/bjc.1992.209

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  144 in total

1.  Down-regulation of a kinase defective PKC-alpha.

Authors:  C Pears; P J Parker
Journal:  FEBS Lett       Date:  1991-06-17       Impact factor: 4.124

2.  Down-regulation of protein kinase C in Swiss 3T3 fibroblasts is independent of its phosphorylating activity.

Authors:  D Lindner; M Gschwendt; F Marks
Journal:  Biochem Biophys Res Commun       Date:  1991-05-15       Impact factor: 3.575

3.  Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.

Authors:  P A Wender; C M Cribbs; K F Koehler; N A Sharkey; C L Herald; Y Kamano; G R Pettit; P M Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

4.  Structural studies on the diglyceride-mediated activation of protein kinase C.

Authors:  L P Molleyres; R R Rando
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

5.  Synthesis and evaluation of neoplastic cell growth inhibition of 1-N-alkylamide analogues of glycero-3-phosphocholine.

Authors:  M H Marx; C Piantadosi; A Noseda; L W Daniel; E J Modest
Journal:  J Med Chem       Date:  1988-04       Impact factor: 7.446

6.  Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations.

Authors:  B S Warren; Y Kamano; G R Pettit; P M Blumberg
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

7.  Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C.

Authors:  A P Fields; G R Pettit; W S May
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

8.  Differential down-regulation of protein kinase C subspecies in KM3 cells.

Authors:  K Ase; N Berry; U Kikkawa; A Kishimoto; Y Nishizuka
Journal:  FEBS Lett       Date:  1988-08-29       Impact factor: 4.124

9.  Contrasting duration of inhibition of cell-cell communication in primary mouse epidermal cells by phorbol 12,13-dibutyrate and by bryostatin 1.

Authors:  G Pasti; E Rivedal; S H Yuspa; C L Herald; G R Pettit; P M Blumberg
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

10.  Protein kinase C activity as marker for colorectal cancer.

Authors:  Y Sakanoue; T Hatada; M Kusunoki; H Yanagi; T Yamamura; J Utsunomiya
Journal:  Int J Cancer       Date:  1991-07-30       Impact factor: 7.396
View more
  12 in total

1.  Activation of protein kinase C-alpha isoform in murine melanoma cells with high metastatic potential.

Authors:  C A La Porta; R Comolli
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

2.  Protein kinase C: a family of isoenzymes with distinct roles in pathogenesis.

Authors:  J M Lord; J Pongracz
Journal:  Clin Mol Pathol       Date:  1995-04

Review 3.  Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis.

Authors:  E M Deacon; J Pongracz; G Griffiths; J M Lord
Journal:  Mol Pathol       Date:  1997-06

4.  Early response gene signalling in bryostatin-stimulated primary B chronic lymphocytic leukaemia cells in vitro.

Authors:  Z Q Ning; T Hirose; R Deed; J Newton; J J Murphy; J D Norton
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

Review 5.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.

Authors:  Stuart A Grossman; Jane B Alavi; Jeffrey G Supko; Kathryn A Carson; Regina Priet; F Andrew Dorr; John S Grundy; Jon T Holmlund
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

7.  Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

Authors:  A T McGown; G Jayson; G R Pettit; M S Haran; T H Ward; D Crowther
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Angiotropic metastatic malignant melanoma in a canine mammary gland.

Authors:  Hai Jie Yang; Eun-Mi Lee; Ah-Young Kim; Eun-Joo Lee; Il-Hwa Hong; Sung-Oh Huh; Kyu-Shik Jeong
Journal:  Lab Anim Res       Date:  2011-12-19

9.  Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.

Authors:  J Prendiville; A T McGown; A Gescher; A J Dickson; C Courage; G R Pettit; D Crowther; B W Fox
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

10.  Induction of cell death by stimulation of protein kinase C in human epithelial cells expressing a mutant ras oncogene: a potential therapeutic target.

Authors:  C A Hall-Jackson; T Jones; N G Eccles; T P Dawson; J A Bond; A Gescher; D Wynford-Thomas
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.